BNP Paribas Arbitrage SA reduced its position in Global Blood Therapeutics Inc (NASDAQ:GBT) by 53.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,599 shares of the company’s stock after selling 75,352 shares during the period. BNP Paribas Arbitrage SA’s holdings in Global Blood Therapeutics were worth $2,920,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Capital Impact Advisors LLC raised its stake in shares of Global Blood Therapeutics by 64.1% in the 2nd quarter. Capital Impact Advisors LLC now owns 48,535 shares of the company’s stock valued at $2,303,000 after purchasing an additional 18,966 shares in the last quarter. Creative Planning acquired a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at about $1,027,000. Fred Alger Management Inc. raised its stake in shares of Global Blood Therapeutics by 297.4% in the 2nd quarter. Fred Alger Management Inc. now owns 31,788 shares of the company’s stock valued at $1,437,000 after purchasing an additional 23,788 shares in the last quarter. Amalgamated Bank raised its stake in shares of Global Blood Therapeutics by 46.5% in the 2nd quarter. Amalgamated Bank now owns 7,624 shares of the company’s stock valued at $345,000 after purchasing an additional 2,420 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in shares of Global Blood Therapeutics by 193.9% in the 2nd quarter. Essex Investment Management Co. LLC now owns 26,537 shares of the company’s stock valued at $1,199,000 after purchasing an additional 17,507 shares in the last quarter. 95.39% of the stock is owned by institutional investors.

In other Global Blood Therapeutics news, Director Deval L. Patrick sold 42,379 shares of the firm’s stock in a transaction that occurred on Friday, July 6th. The shares were sold at an average price of $43.40, for a total value of $1,839,248.60. Following the sale, the director now owns 15,000 shares in the company, valued at $651,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lesley Ann Calhoun sold 3,295 shares of the firm’s stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $44.19, for a total transaction of $145,606.05. Following the completion of the sale, the insider now owns 1,388 shares in the company, valued at approximately $61,335.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,674 shares of company stock worth $2,173,615. 4.40% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on GBT shares. HC Wainwright upped their target price on shares of Global Blood Therapeutics from $73.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, June 27th. Cantor Fitzgerald set a $69.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $70.00 target price on shares of Global Blood Therapeutics in a research note on Thursday, April 26th. SunTrust Banks dropped their price objective on shares of Global Blood Therapeutics from $80.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, May 8th. Finally, Nomura increased their price objective on shares of Global Blood Therapeutics from $91.00 to $109.00 and gave the stock a “buy” rating in a research note on Thursday, June 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $80.20.

GBT opened at $46.00 on Tuesday. The stock has a market cap of $2.41 billion, a P/E ratio of -16.67 and a beta of 4.21. Global Blood Therapeutics Inc has a fifty-two week low of $26.10 and a fifty-two week high of $68.05.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, August 2nd. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09. During the same quarter last year, the business posted ($0.55) EPS. analysts expect that Global Blood Therapeutics Inc will post -3.6 EPS for the current year.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Article: Understanding Stock Ratings

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.